Filing Flows › PTC Therapeutics (PTCT) › Q1 2026
PTC Therapeutics (PTCT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
PTC Therapeutics (PTCT) reported revenue of $273M for the first quarter 2026 (Q1 2026), -77% from a year earlier and +66% from the quarter before. Operating margin was 16.5%, net loss $2.8M (1.0% of revenue).
PTC Therapeutics, Q1 2026: revenue $273M (-77% year over year), operating margin 16.5%, net loss $2.8M, operating cash flow −$59.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $273M | +66% | -77% |
| Operating profit | $45.0M | — | -95% |
| Net earnings | −$2.8M | — | -100% |
| Operating cash flow | −$59.0M | — | -107% |
What changed
Revenue was $272.6M in Q1 2026, down 77% year over year and up 66% from the previous quarter. Sephience was the largest line at 46% of revenue. Collaboration and license revenue lost $986.1M year over year (down 100%), 109% of the total change.
Operating profit was $45.0M, a 16.5% margin (down 66.0 points year over year). Total costs grew 11% against a revenue fall of 77%. The fastest-growing cost line was Other operating costs (+154%). The quarter ended with a net loss of $2.8M, narrower than the previous quarter's $135.0M loss. Net interest and other expense of $47.4M was the main reason.
Operating cash flow was −$59.0M. Non-cash charges added back $15.4M of depreciation and amortization and $23.4M of share-based compensation. Working capital and other items used $95.1M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$60.2M.
Questions
What was PTC Therapeutics' revenue in the first quarter 2026?
PTC Therapeutics (PTCT) reported revenue of $273M for the first quarter 2026 (Q1 2026), -77% from a year earlier and +66% from the quarter before.
Was PTC Therapeutics profitable in the first quarter 2026?
Operating profit was $45.0M (16.5% of revenue) and net loss $2.8M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.